Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 22706245)

1.

Schizophrenia is associated with increased levels of serum Fas and FasL.

Djordjević VV, Ristić T, Lazarević D, Cosić V, Vlahović P, Djordjević VB.

Clin Chem Lab Med. 2012 Feb 10;50(6):1049-54. doi: 10.1515/cclm-2011-0684.

PMID:
22706245
2.

[Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].

Jun EJ, Han JY, Sun HS.

Korean J Hepatol. 2006 Dec;12(4):507-14. Korean.

3.

Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism.

Nabipour I, Kalantarhormozi M, Assadi M, Jafari SM, Gharibi M, Ahmadi E, Sanjdideh Z.

Endocrine. 2010 Dec;38(3):406-11. doi: 10.1007/s12020-010-9401-x. Epub 2010 Nov 2.

PMID:
21042884
4.

[Levels and clinic significance of serum soluble Fas and soluble Fas ligand in coal workers' pneumoconiosis].

Yuan BJ, Liu ZZ, Ding XR, Zou JM.

Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2006 Feb;24(2):96-8. Chinese.

PMID:
16600114
5.

Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.

Tinazzi E, Puccetti A, Gerli R, Rigo A, Migliorini P, Simeoni S, Beri R, Dolcino M, Martinelli N, Corrocher R, Lunardi C.

Int Immunol. 2009 Mar;21(3):237-43. doi: 10.1093/intimm/dxn142. Epub 2009 Jan 30.

6.

Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.

Perianayagam MC, Murray SL, Balakrishnan VS, Guo D, King AJ, Pereira BJ, Jaber BL.

J Lab Clin Med. 2000 Oct;136(4):320-7.

PMID:
11039853
7.

Apoptosis markers soluble Fas (sFas), Fas Ligand (FasL) and sFas/FasL ratio in patients with bacteremia: a prospective cohort study.

Huttunen R, Syrjänen J, Vuento R, Laine J, Hurme M, Aittoniemi J.

J Infect. 2012 Mar;64(3):276-81. doi: 10.1016/j.jinf.2011.12.006. Epub 2011 Dec 19.

PMID:
22207003
8.

[Increased serum soluble Fas ligand in hyperthyroid Graves' disease].

Takeda K, Ohara E, Kaneda T, Hashimoto K, Sasaki M.

Rinsho Byori. 1999 Oct;47(10):961-5. Japanese.

PMID:
10590671
9.

The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.

Yildiz R, Benekli M, Buyukberber S, Kaya AO, Ozturk B, Yaman E, Berk V, Coskun U, Yamac D, Sancak B, Uner A.

J Cancer Res Clin Oncol. 2010 Oct;136(10):1471-6. doi: 10.1007/s00432-010-0803-1. Epub 2010 Feb 13.

PMID:
20155284
10.

Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma.

Boroumand-Noughabi S, Sima HR, Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, Hosseinnezhad H, Moaven O, Rajabi-Mashhadi MT, Azarian AA, Mashhadinejad M, Tavakkol-Afshari J.

BMC Cancer. 2010 Jun 10;10:275. doi: 10.1186/1471-2407-10-275.

11.
12.

Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.

Kuwano K, Maeyama T, Inoshima I, Ninomiya K, Hagimoto N, Yoshimi M, Fujita M, Nakamura N, Shirakawa K, Hara N.

Respirology. 2002 Mar;7(1):15-21.

PMID:
11896896
13.
14.

Serum levels of sFas and sFasL during chemotherapy of lung cancer.

Naumnik W, Izycki T, Ossolinska M, Chyczewska E.

Exp Oncol. 2007 Jun;29(2):132-6.

PMID:
17704746
15.

Circulating soluble Fas ligand correlates with disease activity in Graves' hyperthyroidism.

Wang CY, Zhong WB, Chang TC, Tsai YF.

Metabolism. 2002 Jun;51(6):769-73.

PMID:
12037733
16.

Soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases: relation to humoral immune response markers.

Myśliwiec J, Okota M, Nikołajuk A, Górska M.

Adv Med Sci. 2006;51:119-22.

PMID:
17357290
17.

Serum Fas/FasL levels in dependence on clinical presentations of coronary disease and their relationship with risk factors.

Ristić T, Djordjević VB, Deljanin-Ilić M, Cosić V, Kundalić S.

Vojnosanit Pregl. 2010 Jul;67(7):537-42.

PMID:
20707047
18.

Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.

Xue C, Lan-Lan W, Bei C, Jie C, Wei-Hua F.

Cell Immunol. 2006 Feb;239(2):121-8. Epub 2006 Jun 30. Erratum in: Cell Immunol. 2006 Oct;243(2):127.

PMID:
16808908
19.

Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy.

Guzmán-Fulgencio M, Berenguer J, García-Álvarez M, Micheloud D, C López J, Cosín J, Fernández de Castro I, Catalán P, Miralles P, Resino S.

Eur J Clin Microbiol Infect Dis. 2011 Oct;30(10):1213-21. doi: 10.1007/s10096-011-1215-0. Epub 2011 Mar 26.

PMID:
21442358
20.

[Expression of Fas receptor and soluble Fas ligand (sFasL) concentration in acute leukemia].

Urbaniak-Kujda D, Jaźwiec B, Tomaszewska-Toporska B, Wołowiec D, Kapelko-Słowik K, Kuliczkowski K.

Pol Arch Med Wewn. 2002 Sep;108(3):873-8. Polish.

PMID:
12600184
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk